{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:55:10Z","timestamp":1789379710087,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR304262"],"award-info":[{"award-number":["NIHR304262"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40744-025-00818-x","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T13:27:14Z","timestamp":1766842034000},"page":"27-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic Windows Across the Psoriatic Arthritis Spectrum"],"prefix":"10.1007","volume":"13","author":[{"given":"Ji-Hyoun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"issue":"10","key":"818_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"10136","key":"818_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384.","journal-title":"Lancet"},{"issue":"4","key":"818_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545.","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"818_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"818_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka E, Simon D, d\u2019Oliveira I, Linz C, Lerchen V, Englbrecht M, et al. Disease interception with Interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"818_CR6","first-page":"1251","volume":"56","author":"LC Coates","year":"2017","unstructured":"Coates LC, Gossec L, Ramiro S, Mease P, van der Heijde D, Smolen JS, et al. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017;56(8):1251\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"9999","key":"818_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-Interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"1","key":"818_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"818_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"818_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","volume":"73","author":"E Theander","year":"2014","unstructured":"Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407\u201313.","journal-title":"Ann Rheum Dis"},{"key":"818_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004062","author":"SVJ Snoeck Henkemans","year":"2024","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen LA, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-004062.","journal-title":"RMD Open"},{"issue":"3","key":"818_CR12","first-page":"438","volume":"50","author":"DR Jadon","year":"2023","unstructured":"Jadon DR, Corp N, van der Windt DA, Coates LC, Soriano ER, Kavanaugh A, et al. Management of concomitant inflammatory bowel disease or uveitis in patients with psoriatic arthritis: an updated review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2023;50(3):438\u201350.","journal-title":"J Rheumatol"},{"issue":"4","key":"818_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"10281","key":"818_CR14","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","journal-title":"Lancet"},{"issue":"5","key":"818_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Mechanisms of disease: psoriasis. N Engl J Med. 2009;361(5):496\u2013509.","journal-title":"N Engl J Med"},{"issue":"8","key":"818_CR16","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/art.22758","volume":"56","author":"D McGonagle","year":"2007","unstructured":"McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482\u201391.","journal-title":"Arthritis Rheum"},{"key":"818_CR17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","volume":"66","author":"PJ Mease","year":"2007","unstructured":"Mease PJ, Genovese M, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, et al. Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2-year results from PSA study M02-537. Ann Rheum Dis. 2007;66:419.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"818_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","volume":"73","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde D, Fleischmann R, Wollenhaupt J, Deodhar A, Kielar D, Woltering F, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73(1):233\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"818_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","volume":"78","author":"LJJ van Mens","year":"2019","unstructured":"van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019;78(5):610\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"818_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415\u201329.","journal-title":"Nat Rev Rheumatol"},{"issue":"10230","key":"818_CR21","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"3","key":"818_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"818_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. 2024;15:1331217.","journal-title":"Front Immunol"},{"issue":"9","key":"818_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3899\/jrheum.180971","volume":"46","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol. 2019;46(9):1089\u201396.","journal-title":"J Rheumatol"},{"issue":"1","key":"818_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000806","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden\u2014a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5(1):e000806.","journal-title":"RMD Open"},{"issue":"1","key":"818_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03027-5","volume":"25","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, Ranza R, Ostor A, Ciccia F, Coates LC, Rednic S, et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther. 2023;25(1):56.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"818_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"818_CR28","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","volume":"37","author":"K Schakel","year":"2023","unstructured":"Schakel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"818_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang XY, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"818_CR30","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","volume":"192","author":"S Cheuk","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, Nyl\u00e9n S, Talme T, St\u00e5hle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111\u201320.","journal-title":"J Immunol"},{"key":"818_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1346757","volume":"11","author":"B Lobao","year":"2024","unstructured":"Lobao B, Lourenco D, Giga A, Mendes-Bastos P. From PsO to PsA: the role of T(RM) and Tregs in psoriatic disease, a systematic review of the literature. Front Med. 2024;11:1346757.","journal-title":"Front Med"},{"issue":"7","key":"818_CR32","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/art.41652","volume":"73","author":"EF Leijten","year":"2021","unstructured":"Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 2021;73(7):1220\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"818_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004314","author":"A Zabotti","year":"2024","unstructured":"Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2024-004314.","journal-title":"RMD Open"},{"issue":"2","key":"818_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001067","volume":"5","author":"A Zabotti","year":"2019","unstructured":"Zabotti A, McGonagle DG, Giovannini I, Errichetti E, Zuliani F, Zanetti A, et al. Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia. RMD Open. 2019;5(2):e001067.","journal-title":"RMD Open"},{"issue":"1","key":"818_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","volume":"81","author":"ML Acosta Felquer","year":"2022","unstructured":"Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis. 2022;81(1):74\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"818_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/art.41946","volume":"74","author":"YS Rosenthal","year":"2022","unstructured":"Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case\u2013control study. Arthritis Rheumatol. 2022;74(2):237\u201343.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"818_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"818_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S2665-9913(23)00034-6","volume":"5","author":"S Singla","year":"2023","unstructured":"Singla S, Putman M, Liew J, Gordon K. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023;5(4):200\u20137.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"818_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","volume":"81","author":"E Meer","year":"2022","unstructured":"Meer E, Merola JF, Fitzsimmons R, Love TJ, Wang SY, Shin D, et al. Does biologic therapy impact the development of PsA among patients with psoriasis? Ann Rheum Dis. 2022;81(1):80\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"818_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063650","volume":"12","author":"RH Haberman","year":"2022","unstructured":"Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in preventing arthritis in a multicentre psoriasis at-risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12):e063650.","journal-title":"BMJ Open"},{"issue":"4","key":"818_CR41","doi-asserted-by":"publisher","first-page":"E262","DOI":"10.1016\/S2665-9913(22)00008-X","volume":"4","author":"LC Coates","year":"2022","unstructured":"Coates LC, Tillett W, D\u2019agostino MA, Rahman P, Behrens F, McDearmon-Blondell EL, et al. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. Lancet Rheumatol. 2022;4(4):E262\u201373.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"818_CR42","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2665-9913(25)00223-1","volume":"8","author":"GH Koc","year":"2026","unstructured":"Koc GH, Kok MR, Kasiem FR, Luime JJ, Tchetverikov I, Wilhelm-de Jong K. Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies. Lancet Rheumatol. 2026;8(1):e23\u2013e32. https:\/\/doi.org\/10.1016\/S2665-9913(25)00223-1","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"818_CR43","doi-asserted-by":"publisher","first-page":"e776","DOI":"10.1016\/S2665-9913(25)00156-0","volume":"7","author":"G De Marco","year":"2025","unstructured":"De Marco G, Hensor EMA, Helliwell PS, Sultan S, Dubash SR, Michelena X, et al. Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial. Lancet Rheumatol. 2025;7(11):e776\u201388.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"818_CR44","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1016\/S2665-9913(25)00255-3","volume":"7","author":"DD Gladman","year":"2025","unstructured":"Gladman DD. Challenges in the therapeutic management of psoriatic arthritis. Lancet Rheumatol. 2025;7(11):e749\u201350.","journal-title":"Lancet Rheumatol"},{"key":"818_CR45","doi-asserted-by":"crossref","unstructured":"Massa S, Saeedi E, Francis A, Gullick N, Jadon D, Tillett W, et al. Early intensive therapy with combination csDMARDs or TNF inhibitors are superior to standard step-up care for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED RCT. 2025 Jun 11\u201314; OP0089. European League Against Rheumatism (EULAR) 2025 Congress, Barcelona, Spain.","DOI":"10.1016\/j.ard.2025.05.111"},{"issue":"2","key":"818_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa070","volume":"4","author":"K Geale","year":"2020","unstructured":"Geale K, Lindberg I, Paulsson EC, Wennerstrom ECM, Tjarnlund A, Noel W, et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.","journal-title":"Rheumatol Adv Pract"},{"issue":"5","key":"818_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, Ritchlin CT, den Van Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68(5):702\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"818_CR48","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976\u201386.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"818_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"818_CR50","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150\u20137.","journal-title":"Ann Rheum Dis"},{"key":"818_CR51","doi-asserted-by":"publisher","first-page":"c147","DOI":"10.1136\/bmj.c147","volume":"340","author":"W Sterry","year":"2010","unstructured":"Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.","journal-title":"BMJ"},{"issue":"6","key":"818_CR52","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/annrheumdis-2017-212687","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landewe R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"818_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an Interleukin-17A-specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"818_CR54","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"10370","key":"818_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"IB McInnes","year":"2023","unstructured":"McInnes IB, Asahina A, Coates LC, Landewe R, Merola JF, Ritchlin CT, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25\u201337.","journal-title":"Lancet"},{"issue":"10370","key":"818_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"JF Merola","year":"2023","unstructured":"Merola JF, Landewe R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38\u201348.","journal-title":"Lancet"},{"issue":"3","key":"818_CR57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of Interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"818_CR58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"818_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A Ostor","year":"2022","unstructured":"Ostor A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"818_CR60","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/acr.22576","volume":"68","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, et al. Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care Res (Hoboken). 2016;68(2):267\u201374.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"818_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000723","volume":"4","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2):e000723.","journal-title":"RMD Open"},{"issue":"10","key":"818_CR62","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1007\/s12325-022-02269-0","volume":"39","author":"JR Curtis","year":"2022","unstructured":"Curtis JR, McInnes IB, Rahman P, Gladman DD, Yang F, Peterson S, et al. The effect of guselkumab on general health state in biologic-naive patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Adv Ther. 2022;39(10):4632\u201344.","journal-title":"Adv Ther"},{"key":"818_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003809","author":"S Singla","year":"2024","unstructured":"Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2023-003809.","journal-title":"RMD Open"},{"issue":"9","key":"818_CR64","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/rheumatology\/keae277","volume":"63","author":"L Gossec","year":"2024","unstructured":"Gossec L, Orbai AM, de Wit M, Coates LC, Ogdie A, Ink B, et al. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies. Rheumatology (Oxford). 2024;63(9):2399\u2013410.","journal-title":"Rheumatology (Oxford)"},{"key":"818_CR65","first-page":"2814","volume":"75","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, de Vlam K, Mease PJ, Peloso PM, Wetzel D, Lertratanakul A, et al. Izokibep, a unique IL-17A inhibitor, improves patient-reported outcomes in patients with active psoriatic arthritis up to week 46 phase 2 RCT results. Arthritis Rheumatol. 2023;75:2814\u20136.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"818_CR66","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1038\/s41591-025-03971-6","volume":"31","author":"IB McInnes","year":"2025","unstructured":"McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, et al. Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial. Nat Med 2025;31(12):4160\u20134171. https:\/\/doi.org\/10.1038\/s41591-025-03971-6.","journal-title":"Nat Med"},{"issue":"10230","key":"818_CR67","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"6","key":"818_CR68","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Gladman DD, Poddubnyy D, Chakravarty SD, Shawi M, Kollmeier AP, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther. 2023;10(6):1637\u201353.","journal-title":"Rheumatol Ther"},{"key":"818_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2342383","author":"JF Merola","year":"2024","unstructured":"Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue CY, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatol Treat. 2024. https:\/\/doi.org\/10.1080\/09546634.2024.2342383.","journal-title":"J Dermatol Treat"},{"issue":"9","key":"818_CR70","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Chohan S, Fructuoso FJG, Luggen ME, Rahman P, Raychaudhuri SP, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021;80(9):1147\u201357.","journal-title":"Ann Rheum Dis"},{"key":"818_CR71","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2022-eular.2456","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar A, Van der Heijde D, Behrens F, Kivitz A, Neal J, et al. Safety and efficacy of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis: 52-week results from a randomised phase 2 trial. Ann Rheum Dis. 2022;81:842\u20133.","journal-title":"Ann Rheum Dis"},{"key":"818_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.023","author":"A Kivitz","year":"2025","unstructured":"Kivitz A, Baraliakos X, Muensterman ET, Kavanaugh A, van der Heijde D, Klimiuk PA, et al. Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study. Ann Rheum Dis. 2025. https:\/\/doi.org\/10.1016\/j.ard.2025.05.023.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"818_CR73","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s13555-025-01454-7","volume":"15","author":"B Knight","year":"2025","unstructured":"Knight B, Tammara B, Modi NB, Dallas S, Mardirosian S, Wang J, et al. Translational pharmacokinetics of icotrokinra, a targeted oral peptide that selectively blocks Interleukin-23 receptor and inhibits signaling. Dermatol Ther Heidelb. 2025;15(9):2495\u2013520.","journal-title":"Dermatol Ther Heidelb"},{"issue":"11","key":"818_CR74","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/rheumatology\/key173","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, et al. Dual inhibition of tumour necrosis factor and Interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford). 2018;57(11):1972\u201381.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00818-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T16:03:19Z","timestamp":1768838599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00818-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00818-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laura Coates is an Editorial Board member of\n                      Rheumatology and Therapy\n                      . Laura Coates was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ji-Hyoun Kang has nothing to disclose. Laura C Coates has received grants\/research support from AbbVie, Amgen, Janssen, and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Enlivex, Janssen, Moonlake, Novartis, Pfizer, Proximi-T, Takeda and UCB; and has been paid as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}